Compass Pathways (NASDAQ:CMPS) Sets New 12-Month High - Should You Buy?

Key Points

• Compass Pathways shares reached a new 52-week high of $15.87 and last traded at $15.17, up from the prior close of $14.04.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $23.36, though ratings range from Strong Buy to Sell.
• The clinical-stage biotech reported a significant quarterly EPS miss, posting a loss of $1.88 versus the expected loss of $0.39; institutional investors own 46.19% of the company.

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report)'s stock price hit a new 52-week high during trading on Thursday . The company traded as high as $15.87 and last traded at $15.17, with a volume of 7718228 shares traded. The stock had previously closed at $14.04.

Wall Street Analyst Weigh In

CMPS has been the subject of a number of research reports. Wells Fargo & Company initiated coverage on Compass Pathways in a report on Monday, July 27th. They set an "equal weight" rating and a $13.00 target price for the company. TD Cowen reaffirmed a "buy" rating on shares of Compass Pathways in a research report on Monday, June 1st. Canaccord Genuity Group increased their price objective on Compass Pathways from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Friday, June 26th. HC Wainwright dropped their target price on Compass Pathways from $70.00 to $65.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. Finally, Raymond James Financial reaffirmed a "buy" rating on shares of Compass Pathways in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.36.

Compass Pathways Stock Performance

The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -3.28 and a beta of 2.54. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The stock's 50 day moving average is $13.09 and its 200 day moving average is $10.50.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). Analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.26 earnings per share for the current year.

Institutional Investors Weigh In On Compass Pathways

A number of institutional investors have recently modified their holdings of CMPS. WINTON GROUP Ltd increased its position in Compass Pathways by 20.1% during the second quarter. WINTON GROUP Ltd now owns 17,900 shares of the company's stock worth $253,000 after acquiring an additional 3,000 shares during the period. Integrated Wealth Concepts LLC acquired a new position in shares of Compass Pathways during the 2nd quarter worth approximately $351,000. Squarepoint Ops LLC increased its holdings in shares of Compass Pathways by 751.1% during the second quarter. Squarepoint Ops LLC now owns 138,671 shares of the company's stock worth $1,962,000 after purchasing an additional 122,378 shares during the period. TD Waterhouse Canada Inc. raised its position in shares of Compass Pathways by 4,292.2% in the second quarter. TD Waterhouse Canada Inc. now owns 30,306 shares of the company's stock valued at $402,000 after buying an additional 29,616 shares in the last quarter. Finally, Ancora Advisors LLC bought a new stake in shares of Compass Pathways in the second quarter valued at approximately $43,000. Institutional investors own 46.19% of the company's stock.

About Compass Pathways

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.